Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 469

1.

Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice.

Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, Lu S, Jiang XC.

J Biol Chem. 2005 Mar 18;280(11):10284-9. Epub 2004 Dec 6.

2.

Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.

Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD.

Circulation. 2004 Nov 30;110(22):3465-71. Epub 2004 Nov 15.

3.

Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.

Glaros EN, Kim WS, Wu BJ, Suarna C, Quinn CM, Rye KA, Stocker R, Jessup W, Garner B.

Biochem Pharmacol. 2007 May 1;73(9):1340-6. Epub 2006 Dec 27.

PMID:
17239824
4.

Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice.

Park TS, Rosebury W, Kindt EK, Kowala MC, Panek RL.

Pharmacol Res. 2008 Jul;58(1):45-51. doi: 10.1016/j.phrs.2008.06.005. Epub 2008 Jun 20.

PMID:
18611440
5.

Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice.

Lee BJ, Kim JS, Kim BK, Jung SJ, Joo MK, Hong SG, Kim JS, Kim JH, Yeon JE, Park JJ, Byun KS, Bak YT, Yoo HS, Oh S.

J Gastroenterol Hepatol. 2010 Jun;25(6):1105-10. doi: 10.1111/j.1440-1746.2010.06246.x.

PMID:
20594226
6.

Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin.

Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T.

Biochem Biophys Res Commun. 1995 Jun 15;211(2):396-403.

PMID:
7794249
7.

Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice.

Glaros EN, Kim WS, Quinn CM, Jessup W, Rye KA, Garner B.

J Lipid Res. 2008 Feb;49(2):324-31. Epub 2007 Oct 31.

9.

Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice.

Hojjati MR, Li Z, Jiang XC.

Biochim Biophys Acta. 2005 Oct 15;1737(1):44-51. Epub 2005 Aug 24.

PMID:
16216550
10.

Disruption of sphingolipid homeostasis by myriocin, a mycotoxin, reduces thymic and splenic T-lymphocyte populations.

Johnson VJ, He Q, Osuchowski MF, Sharma RP.

Toxicology. 2004 Sep 1;201(1-3):67-75.

PMID:
15297021
11.

Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction.

Dekker MJ, Baker C, Naples M, Samsoondar J, Zhang R, Qiu W, Sacco J, Adeli K.

Atherosclerosis. 2013 May;228(1):98-109. doi: 10.1016/j.atherosclerosis.2013.01.041. Epub 2013 Feb 10.

PMID:
23466071
12.
13.

Effect of high fat diet enriched with unsaturated and diet rich in saturated fatty acids on sphingolipid metabolism in rat skeletal muscle.

Blachnio-Zabielska A, Baranowski M, Zabielski P, Gorski J.

J Cell Physiol. 2010 Nov;225(3):786-91. doi: 10.1002/jcp.22283.

PMID:
20568228
14.

FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA.

Circulation. 2007 Jan 30;115(4):501-8. Epub 2007 Jan 22.

15.

Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?

Tabas I.

Circulation. 2004 Nov 30;110(22):3400-1. No abstract available.

16.

Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.

Atkinson RD, Coenen KR, Plummer MR, Gruen ML, Hasty AH.

Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E284-90. Epub 2007 Nov 20.

17.

cis-4-Methylsphingosine decreases sphingolipid biosynthesis by specifically interfering with serine palmitoyltransferase activity in primary cultured neurons.

van Echten-Deckert G, Zschoche A, Bär T, Schmidt RR, Raths A, Heinemann T, Sandhoff K.

J Biol Chem. 1997 Jun 20;272(25):15825-33.

18.

Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate.

Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH Jr, Futerman AH.

J Biol Chem. 2008 Feb 29;283(9):5677-84. doi: 10.1074/jbc.M707386200. Epub 2007 Dec 28.

19.

Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice.

Glaros EN, Kim WS, Rye KA, Shayman JA, Garner B.

J Lipid Res. 2008 Aug;49(8):1677-81. doi: 10.1194/jlr.E800005-JLR200. Epub 2008 May 8.

20.

Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.

Kitayama K, Nishizawa T, Abe K, Wakabayashi K, Oda T, Inaba T, Amemiya Y.

J Pharm Pharmacol. 2006 Dec;58(12):1629-38.

PMID:
17331327

Supplemental Content

Support Center